Genistein (19) treatment reduced liver inflammation and fibrosis through a decrease in TNF-α and IL-1β levels in mice with MCD diet-induced NASH (Yoo et al., 2015). This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.